GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Reports Full Year 2017 Financial Results

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology

GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update

GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Participate in Multiple Conferences in November